Clinical Trial Update: CtDNA Based MRD Testing for NAC Monitoring in TNBC

View source ↗

Summary

This clinical trial update describes a study evaluating ctDNA-based minimal residual disease testing to monitor neoadjuvant chemotherapy in triple-negative brea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: Personalis Inc. | Conditions: TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease | Status: RECRUITING